Immune responses to borrelial VlsE IR6 peptide variants

International Journal of Medical Microbiology

Volumn 297, Issue 1, 2007, Pages 45-52

  Sillanpää, Heidi ^a   Lahdenne, Pekka ^b   Sarvas, Heikki ^a,c   Arnež, Maja ^d   Steere, Allen ^e   Peltomaa, Miikka ^e   Seppälä, Ilkka ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Borrelia; C6; ELISA; IR6 peptide; Lyme disease

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PEPTIDE; PEPTIDE ANTIBODY; PROTEIN V1SE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL STRAIN; BORRELIA; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FACIAL NERVE PARALYSIS; HUMAN; IMMUNE RESPONSE; LYME DISEASE; NONHUMAN; NORTH AMERICA; PROTEIN VARIANT; SERODIAGNOSIS; SERUM;

EID: 33846415498     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2006.09.001     Document Type: Article

References (28)

1. Anthonissen F.M., De Kesel M., Hoet P.P., and Bigaignon G.H. Evidence for the involvement of different genospecies of Borrelia in the clinical outcome of Lyme disease in Belgium. Res. Microbiol. 145 (1994) 327-331
2. Bacon R.M., Biggerstaff B.J., Schriefer M.E., Gilmore Jr. R.D., Philipp M.T., Steere A.C., Wormser G.P., Marques A.R., and Johnson B.J.B. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J. Infect. Dis. 187 (2003) 1187-1199
3. Brown S.L., Hansen S.L., and Langone J.J. Role of serology in the diagnosis of Lyme disease. JAMA 282 (1999) 62-66
4. Carlsson S.A., Granlund H., Jansson C., Nyman D., and Wahlberg P. Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections. Scand. J. Infect. Dis. 35 (2003) 31-33
5. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the second international conference on serologic diagnosis of Lyme disease. Morb. Mortal. Wkly. Rep. 44 (1995) 590-591
6. Gottner G., Schulte-Spechtel U., and Wilske B. Heterogeneity of the immunodominant surface protein VlsE among the three genospecies of Borrelia burgdorferi pathogenic for humans. Int. J. Med. Microbiol. 293 Suppl. 37 (2004) 172-173
7. Heikkilä T., Huppertz H.I., Seppälä I., Sillanpää H., Saxen H., and Lahdenne P. Recombinant or peptide antigens in the serology of Lyme arthritis in children. J. Infect. Dis. 187 (2003) 1888-1894
8. Hengge U.R., Tannapfel A., Tyring S.K., Erbel R., Arendt G., and Ruzicka T. Lyme borreliosis. Lancet Infect. Dis. 3 (2003) 489-500
9. Hubálek Z., and Halouzka J. Distribution of Borrelia burgdorferi sensu lato genomic groups in Europe, a review. Eur. J. Epidemiol. 13 (1997) 951-957
10. Lawrenz M.B., Hardham J.M., Owens R.T., Nowakowski J., Steere A.C., Wormser G.P., and Norris S.J. Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi. J. Clin. Microbiol. 37 (1999) 3997-4004
11. Liang F.T., Alvarez A.L., Gu Y., Nowling J.M., Ramamoorthy R., and Philipp M.T. An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J. Immunol. 163 (1999) 5566-5573
12. Liang F.T., Steere A.C., Marques A.R., Johnson B.J., Miller J.N., and Philipp M.T. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J. Clin. Microbiol. 37 (1999) 3990-3996
13. Liang F.T., Aberer E., Cinco M., Gern L., Hu C.M., Lobert Y.N., Ruscio M., Voet Jr. P.E., Weynants V.E., and Philipp M.T. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi s.l. J. Infect. Dis. 182 (2000) 1455-1462
14. Logar M., Ruzic-Sabljic E., Maraspin V., Lotric-Furlan S., Cimperman J., Jurca T., and Strle F. Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii. Infection 32 (2004) 15-19
15. Manea M., Hudecz F., Przybylski M., and Mezo G. Synthesis, solution conformation, and antibody recognition of oligotuftsin-based conjugates containing a β-amyloid(4-10) plaque-specific epitope. Bioconjugate Chem. 16 (2005) 921-928
16. Nadelman R.B., and Wormser G.P. Lyme borreliosis. Lancet 352 (1998) 557-565
17. Nowakowski J., Schwartz I., Liveris D., Wang G., Aquero-Rosenfeld M.E., Girao G., McKenna D., Nadelman R.B., Cavaliere L.F., Wormser G.P., and the Lyme disease study group. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin. Infect. Dis. 33 (2001) 2023-2027
18. Oksi J., Marttila H., Soini H., Aho H., Uksila J., and Viljanen M.K. Early dissemination of Borrelia burgdorferi without generalized symptoms in patients with erythema migrans. APMIS 109 (2001) 581-588
19. Peltomaa M., McHugh G., and Steere A.C. Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. J. Infect. Dis. 187 (2003) 1178-1186
20. Peltomaa M., McHugh G., and Steere A.C. The VlsE (IR6) peptide ELISA in the serodiagnosis of Lyme facial paralysis. Otol. Neurol. 25 (2004) 838-841
21. Steere A.C. Lyme disease. N. Engl. J. Med. 345 (2001) 115-125
22. Tugwell P., Dennis D.T., Weinstein A., Wells G., Shea B., Nichol G., Hayward R., Lightfoot R., Baker P., and Steere A.C. Laboratory evaluation in the diagnosis of Lyme disease. Ann. Intern. Med. 127 (1997) 1109-1123
23. van Dam A.P., Kuiper H., Vos K., Widjojokusumo A., de Jongh B.M., Spanjaard L., Ramselaar A.C., Kramer M.D., and Dankert J. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17 (1993) 708-717
24. Wang D., Botkin D.J., and Norris S.J. Characterization of the vls antigenic variation loci of the Lyme disease spirochaetes Borrelia garinii Ip90 and Borrelia afzelii ACAI. Mol. Microbiol. 47 (2003) 1407-1417
25. Wharton M., Chorba T.L., Vogt R.L., Morse D.L., and Buehler J.W. Case definitions for public health surveillance. MMWR Recomm. Rep. 39 (1990) 1-43
26. Wormser G.P., Aguero-Rosenfeld M.E., and Nadelman R.B. Lyme disease serology: problems and opportunities. JAMA 282 (1999) 79-80
27. Wormser G.P., Nadelman R.B., Dattwyler R.J., Dennis D.T., Shapiro E.D., Steere A.C., Rush T.J., Rahn D.W., Coyle P.K., Persing D.H., Fish D., and Luft B.J. Practice guidelines for the treatment of Lyme disease. The infectious diseases society of America. Clin. Infect. Dis. 31 Suppl. 1 (2000) 1-14
28. Zhang J.R., Hardham J.M., Barbour A.G., and Norris S.J. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 89 (1997) 275-285